Durvalumab vs Triptorelin Pamoate

## Durvalumab vs Triptorelin Pamoate: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Triptorelin Pamoate**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Triptorelin Pamoate — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Triptorelin Pamoate — Protein.